IBI3027 (dupilumab biosimilar)
/ Innovent Biologics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 11, 2026
A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis
(clinicaltrials.gov)
- P3 | N=520 | Not yet recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
New P3 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
1 to 1
Of
1
Go to page
1